Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities

Moderna Inc. (NASDAQ:MRNA) on Thursday revealed its next growth phase during its 2026 Analyst Day, emphasizing the expansion of its mRNA platform into multiple therapeutic areas.

The biotechnology firm raised its 2026 revenue growth forecast and provided detailed updates on commercial strategies, oncology advancements and manufacturing efficiencies.

Commercial Expansion and Oncology Advancements

The company aims to build durable franchises across infectious diseases, individualized cancer therapies and rare genetic liver conditions. A key focus remains intismeran, an investigational individualized neoantigen therapy developed alongside Merck & Co., Inc. (NYSE:MRK).

Following positive Phase 3 results in adjuvant melanoma, the treatment is advancing toward potential commercialization, subject to regulatory approval.

Commercial growth drivers for 2027 and beyond include the broader launch of the seasonal influenza vaccine, mFLUSIVA. Moderna also anticipates European expansion as a rival COVID-19 vaccine contract concludes.

Long-term agreements in the U.K., Canada and Australia provide recurring revenue and support domestic manufacturing, while new agreements in Mexico and Taiwan expand its reach in Latin America and Asia-Pacific.

Manufacturing Automation and Financial Upgrades

Manufacturing serves as a cornerstone for this integrated strategy. The Marlborough, Massachusetts, facility currently supplies clinical materials for intismeran and will become the global supply hub by 2027.

Moderna utilizes advanced automation and robotics at this site to accelerate turnaround times and lower production costs.

The company and Merck plan to co-promote intismeran in the U.S., while Merck handles international commercialization.

Financially, Moderna upgraded its 2026 revenue growth projection to a range of 15% to 25%, compared with its original outlook of up to 10%. The company said it is on track for about 10 percentage points of gross margin expansion this year, excluding a litigation settlement charge.

By accelerating cost reductions, the company shifted its 2027 cash cost framework forward into 2026.

Moderna expects annual cash costs of about $4 billion to $4.5 billion from 2027 through 2030, driven mainly by increased investment in oncology.

Furthermore, Moderna secured better terms on its $1.5 billion credit facility with Ares Management (NYSE:ARES) credit funds, extending the maturity by one year to 2031 and cutting the interest rate on drawn amounts by 75 basis points.

The company anticipates closing 2026 with roughly $9 billion in total liquidity.

MRNA Price Action: Moderna shares were down 3.75% at $239.36 at the time of publication Thursday, according to Benzinga Pro data.

Photo: Josh Morgan / USA TODAY Network via Reuters Connect